The changing dynamics of eClinical: Why configurability is king
Clinical trial sponsors are navigating a landscape of increasing complexity. A team of researchers recently set out to explore this …
Clinical trial sponsors are navigating a landscape of increasing complexity. A team of researchers recently set out to explore this …
Acumen Pharmaceuticals has dosed the first subject in the open-label extension (OLE) segment of its Phase II Altitude-AD trial of …
Nuvalent’s stock price oscillated after it’s investigational ALK-selective inhibitor showed promise in patients with advanced ALK-positive non-small cell lung cancer …
Roche has reported encouraging outcomes from its Phase III lidERA Breast Cancer trial of oral giredestrant as an adjuvant endocrine …
As AI and technology are changing the way clinical trial data is managed, the next question is how this should …
ReCode Therapeutics has initiated the third part of its Phase II clinical trial of the inhaled cystic fibrosis transmembrane conductance …
On 10 November 2025, the revocation of Canada's measles elimination status was announced by the Pan American Health Organization (PAHO). …
Novotech, a global full-service contract research organization, won the Research and Development and Marketing awards in the 2025 Clinical Trials …
Agomab Therapeutics is taking its lead candidate, ontunisertib, to a Phase IIb trial following its mid-stage success in fibrostenosing Crohn’s …
Editor’s note: This article has been updated to clarify that the collaboration was with Johnson & Johnson, not AstraZeneca as …
Cancer Research UK is set to initiate a trial of a vaccine aimed at preventing lung cancer in patients at …
Samson Clinical has concluded participant enrolment for its SAM-002 Phase III clinical trial assessing sublingual minoxidil in male pattern hair …
In recent years, automation and artificial intelligence (AI) have been huge trends within the clinical trials landscape, as companies look …
is is the fourth episode in our Insights Uncovered: A Real-World Data Podcast Series, exploring the evolving landscape of real-world …
Gilead Sciences is preparing to file for approval of its single-tablet anti-retroviral therapy (ART) combination in human immunodeficiency virus (HIV) …